Abstract
Mitochondria and cell death
The mitochondrial 'intrinsic' pathway and the death receptor 'extrinsic' pathway are the two principal pathways leading to apoptosis, both of which converge on caspase activation (Fig. 1 ) [1] [2] [3] . Caspases are a family of cysteine proteases that, upon activation, cleave specific substrates, leading to the demise of the cell. Based on the order of activation in cell death pathways, caspases are divided into two major groups: initiator caspases and executioner caspases [4] . The subset of caspases that cleave substrates to produce the typical biochemical changes associated with apoptosis are known as executioner caspases, which in mammals are caspases-3, -6 and -7 [5] . (CARD) and are involved in interacting with the upstream adapter molecules. The initiator caspases are activated by prodomain-mediated dimerization of the zymogens followed by autocatalytic processing [6] . The initiator caspase for the mitochondrial pathway is caspase-9, whereas the initiator caspases for the death receptor pathway are caspases-8 and -10 [7] . Both pathways share the effector caspases (caspases-3, -6 and -7) which cleave cellular substrates leading to apoptotic cell death. Furthermore, caspase-2 is a long prodomain containing initiator caspase involved in stress-induced apoptosis [8] . A protein complex, named PIDDosome has been shown to mediate the activation of caspase-2 in response to genotoxic stimuli [9] . In addition to caspase-2, the PIDDosome contains the p53-induced protein with a death domain (PIDD) and an adapter protein, called RAIDD. Caspase-2 has also been suggested to induce mitochondrial cytochrome c release through a mechanism not yet understood [10, 11] . Caspases-1, -4, -5 and -11 function primarily in the processing of inflammatory cytokines through another proteolytic platform called the inflammosome [12] . Fig. 1) [25, 26] . In this manner, the death signal may be amplified through formation and activation of the apoptosome which contributes to effector caspase activation. [34] . The [35] [33] .
Executioner caspases have a short pro-domain and are in turn activated by apical initiator caspases (caspases-2, -8, -9 and -10). Initiator caspases possess long prodomains that contain one of the two characteristic protein-protein interaction motifs: the death effector domain or the caspase recruitment domain

Death signals originating from cellular stress, including radiation, oxidative stress, genotoxic stress and chemotherapeutic drugs, activate an intrinsic apoptotic pathway that is mediated largely by the mitochondria. Mitochondrial release of cytochrome c into the cytoplasm induces the formation of a multiprotein complex called the apoptosome. Apoptosome contains among others cytochrome c, pro-caspase-9 and the adaptor protein Apaf-1 [13] and, supports the activation of caspase-9 through enforced multimerization, which in turn cleaves and activates the effector caspase-3 resulting in the subsequent degradation of cellular death substrates (Fig. 1) [14]. In addition to cytochrome c, other mitochondrial proteins released during apoptosis have been identified over the past decade and these include second mitochondriaderived activator of caspase/direct inhibitor of apoptosis protein (IAP) binding protein with a low pI, (Smac/DIABLO), endonuclease G (Endo G), apoptosis-inducing factor (AIF), HtrA2/Omi [15], as well as Hsp60, Hsp10 and adenylate kinase [16] (Fig. 1). Some intermembrane space (IMS) proteins have essential survival functions in mitochondria and a well-established lethal function in the cytosol. In the extrinsic pathway, ligation of death receptors (a subset of the tumour necrosis factor [TNF] receptor [TNFR] family, including TNFR-1, CD95, TNF-related apoptosis-inducing ligand receptors-1 and -2 [TRAIL-R1 and -R2] and DR3/TRAMP) causes the recruitment and oligomerization of the adapter molecule Fasassociated death domain (FADD) within the death-inducing signalling complex (DISC) [17]. The oligomerized FADD binds pro-caspases-8 and -10, causing their homodimerization and activation (Fig. 1) [18-22]. Depending on the cell type, activated caspase-8 induces apoptosis by two different signalling pathways [23]. In type I cells, large amounts of active caspase-8 formed at the DISC directly induces activation of pro-caspase-3 independently of mitochondria [24]. In type II cells, probably only a low amount of active caspase-8 is generated that is unable to activate sufficient amounts of pro-caspase-3 directly to a level that would be sufficient to execute apoptosis. In these cells, caspase-8 cleaves the 'Bcl-2 homology (BH) 3-only protein' Bid, generating an active fragment (tBid) that activates the mitochondrial death pathway (
MOMP by BCL-2 family proteins
The first model considers MOMP as a process that is essentially intrinsic to the outer membrane and controlled by members of the BCL-2 family of proteins to promote or prevent the formation of large, protein permeable pores (Fig. 2). The BCL-2 family of proteins is divided into three groups, based on the presence of BCL-2 homology domains (BH1-4 domains)
multidomain, anti-apoptotic BCL-2 proteins (e.g. BCL-2, BCL-w, BCL-xL [BCL-2 related gene, long isoform], A1 and MCL-1 [myeloid cell leukaemia 1]] contain BH domains 1-4 and are generally localized to various intracellular membranes such as outer mitochondrial membrane, endoplasmic reticulum (ER) membrane and nuclear membrane
MOMP by permeability transition pore
The second prominent model for MOMP is based on a phenomenon known as the mitochondrial permeability transition (MPT) (Fig. 2) . PT [112] . The oncoprotein, prothymosin-A, inhibits the formation of the apoptosome, while tumour suppressor putative HLA-DR-associated proteins facilitate apoptosome-mediated pro-caspase-9 activation [113] .
by Hsp27, prevents induction of apoptosis in a model of PD [81]. Tumour up-regulated CARD-containing antagonist of caspase-9 binds pro-caspase-9 by its CARD domain, thereby preventing its interaction with Apaf-1 [110, 111]. Phosphorylation of caspase-9 by extracellular signal-regulated kinase (ERK) 1/2 at Threonine-125 prevents proteolytic processing and activation of pro-caspase-9 without affecting its recruitment to apoptosome
IAPs are involved in the regulation of apoptosome function and are characterized by the presence of the baculoviral IAP repeat (BIR) domain [114] . XIAP regulates activity of initiator and effector caspases through different mechanisms [115] . An active effector caspase, such as caspase-7, exists as a homodimer and contains two active sites, one on each monomer. The active site of caspase-7 can be tightly bound by a short peptide sequence in the linker region preceding the BIR2 domain of XIAP [116] . This binding blocks substrate entry resulting in the inhibition of caspase-7 [116] . An initiator caspase, such as caspase-9 exists as monomer and BIR3 of XIAP interacts with caspase-9 monomer, thereby trapping caspase-9 in its monomeric state [117] . XIAP-mediated steric hindrance thereby prevents homodimerization-induced activation of caspase-9 and retains a caspase-9 monomer in its inactive state [117] . The Ring domain which has an E3 ubiquitin ligase activity promotes ubiquitination and subsequent degradation of pro-caspases-3 and -9 [118, 119] [141] and mitochondrial calcium overload both of which, have the capacity to induce opening of the MTP pore (permeability transition pore complex [PTPC] ). PTPC opening has been observed in many models of ischemia/reperfusion [142] , and cytochrome c release has been observed following reperfusion of the ischemic brain [143] . In many cases, the cell death is preventable by agents that act at the level of the mitochondria. For example, treatments that are known to prevent PTPC opening seem to protect tissue from damage [144] . 
Mitochondrial pathway of cell death and disease pathogenesis
It is evident that defects in the apoptotic machinery or aberrations in apoptotic responses to death signals can contribute to various human diseases. MOMP-dependent apoptosis is involved in major pathologies, with far-reaching medical and pharmaceutical implications. Mitochondria are involved in several known human diseases, including ischemia-reperfusion injury of the heart, ischemic and traumatic brain damage, muscular dystrophy caused by collagen VI deficiency, amyotrophic lateral sclerosis (ALS), acetaminopheninduced hepatotoxicity, hepatocarcinogenesis induced by 2-acetylaminofluorene and death receptor induced hepatitis [140].
Ischemia/reperfusion
Ischemia is the process whereby the blood supply of an organ is interrupted and results in cell death, most likely due to disruption of cellular energy metabolism such as loss of ATP. Injury following reoxygenation may be due in part to the formation of ROS
Neurodegenerative disorders
Apoptotic pathways and specifically MOMP is involved in the pathophysiology of widespread and devastating neurodegenerative disorders (reviewed in [145] ). Imaging studies of postmortem brain tissue have revealed apoptotic nuclei in patients with Alzheimer's disease [146] , ALS [147] , Huntington's disease (HD) [148] and PD [149] .
Alzheimer's disease is characterized by a general decrease in cognitive ability, especially short-term memory [150] . In addition to postmortem nuclei suggestive of apoptosis, certain proteins with apoptotic potential were modulated in the brains of Alzheimer's patients [150] . BCL-2 expression was decreased and BAX was up-regulated in neurons with neurofibrillary tangles [151] . Reduced complexes II, III and IV activity is seen postmortem in AD brains [152] . [154] .
Presenilins are genes that were originally isolated due to their ability to induce an early-onset form of familial AD. Mutations in presenilin-1 (PS-1) increase neuronal sensitivity to ischemia, hyperosmotic shock and calcium overload [153]. PS-1 and PS-2 have been demonstrated to bind antiapoptotic BCL-xL and at least PS-2 can modulate mitochondrial apoptosis, presumably through inactivation of anti-apoptotic BCL-2 family members
PD is characterized clinically by bradykinesia, rigidity and tremor, which correlates histologically with a loss of dopaminergic neurons in the substantia nigra pars compacta [155] . Impairment of complex I and subsequent oxidative stress have been widely demonstrated in experimental models of PD and in postmortem PD samples [156] . In neuronal culture, dopamine (DA) has been shown to result in apoptotic cell death in a dose-dependent manner [157] . Moreover, BCL-2 overexpression, seen in vivo in surviving DA neurons in the substantia nigra [158] , is also able in vitro to abrogate DA-induced cell death, suggesting mitochondrial involvement in the death process [157] .
HD is a dominantly inherited neuromotor disease characterized by involuntary, hyperkinetic movements, retardation of voluntary movements and cognitive impairment [159] . The disease is caused by expanded CAG repeats within the huntingtin gene, and degeneration of neurons in specific brain regions [159] . [163, 164] . A proportion of SOD1 has been shown to localized to mitochondrial intermembrane space [165, 166] and matrix [167] [193] .
Therapeutic strategies that promote MOMP and cell death
There are a number of drugs that are aimed to induce apoptosis by targeting components of the mitochondrial pathway to induce MOMP. A summary of the agents that promote MOMP and cell death can be found in Table 1 . (Fig. 3 ) [194] [195] [196] [197] . [198] [199] [200] . Oblimersen sodium has advanced through clinical trials, including phase III with tolerable side effects [201] [201] . [200, 202] . Thus, the efficacy of BCL-2 antisense strategies has not been overwhelming, and approval of oblimersen as an anticancer agent remains in doubt. [203] . BAX, which normally resides in the cytoplasm, translocates to mitochondria in response to apoptotic stimuli, promotes MOMP and elicits the release of pro-apoptotic factors from the intermembrane space [33] . Adenovirus-mediated BAX overexpression is capable of inducing cell death in vitro and in vivo by engaging the mitochondrial pathway [204] [205] [206] . [207] .
Targeting the BCL-2 family
The ratio of the levels of pro-survival and pro-apoptotic members of the BCL-2 protein family is thought to be an important regulatory factor for determining mitochondrial integrity and regulates the sensitivity of mammalian cells to apoptotic stimuli. This information has, in the early days of apoptosis research, led to the consideration of BCL-2 family members as possible therapeutic targets for diseases with deregulated apoptosis
The following section describes various approaches developed around the members of BCL-2 family.
BCL-2 antisense-based strategies BCL-2 (B-cell lymphoma 2) is an oncoprotein, which was originally identified as the t(14;18) chromosomal translocation found in the majority of human follicular lymphomas [194]. BCL-2 plays a critical role in inhibiting mitochondria-dependent apoptotic cell death. Its pathologic over-expression observed in many tumour types identified BCL-2 as a possible drug target in the early 1990s. Because BCL-2 is an intracellular protein lacking intrinsic catalytic function, its inhibition by neutralizing antibodies or small molecule drugs are not viable options. On the other hand, in several preclinical and clinical studies antisense BCL-2 therapy combined with chemotherapy has proven to be beneficial in various tumour types. Antisense BCL-2 (AS BCL-2; G3139, oblimersen sodium,
Genasense, Genta, Berkeley Heights, NJ, UDA) is an 18-bp phosphorothioate oligonucleotide targeting the first six codons of BCL-2 mRNA. In preclinical studies, the treatment with antisense BCL-2 in combination with an anticancer drug decreased BCL-2 expression and enhanced the mitochondria-dependent apoptosis pathway leading to cell death
(www.clinicaltrial.com). However, the demonstration of efficacy of antisense BCL-2 in those trials has been variable. In chronic lymphocytic leukaemia, combined oblimersen, fludarabine and cyclophosphamide showed improved major responses in patients, whereas oblimersen and dacarbazine combination therapy in patients with metastatic melanoma or oblimersen and dexamethasone combination therapy in patient with myeloma provided no significant benefit in overall survival. In addition, in these clinical trials the down-regulation of BCL-2 was not observed with any high frequency in tumour cells
In fact, in addition to its antisense effect, several non-antisense effects need to be considered when analyzing the therapeutic efficacy of antisense BCL-2 observed in clinical trials. Production of ROS, interferon (IFN)-␥ production and immunostimulatory action through a cytosine-phosphate-guanosine motif in the antisense oligodeoxynucleotides might contribute to the antitumour effects
BAX-delivery vector BAX is one of the pro-apoptotic factors that belong to the BCL-2 family, and its overexpression leads to apoptosis in a wide variety of mammalian cells
Through its BH3 domain, BAX forms homodimers to promote apoptosis but also forms heterodimers with BCL-2 and BCL-xL, which silences its function. Likewise, adenovirus-mediated gene delivery of an amino-terminal truncated version of BAX (⌬N BAX: corresponding to amino acid 112-192 of full-length BAX), that cannot be suppressed by the anti-apoptotic BCL-2 family members has been generated. Interestingly, ⌬N BAX exhibited a significantly stronger suppression of tumour growth than full-length BAX, suggesting that the truncated version of BAX may provide a better alternative for gene therapy trials
BH3 mimetic peptides Pro-apoptotic multidomain members of the BCL-2 family (BAK, BAX) are activated by BH3-only proteins (such as BAD, BID, BIM, PUMA, NOXA) to induce mitochondrial apoptotic death events, and BH3 domains are necessary and sufficient for this effect [208]. The interaction between these BCL-2 family members is primarily mediated through the amphipathic ␣-helices of their BH3 domains [209]. BH3-only proteins act in two ways, either by inactivation of the anti-apoptotic BCL-2 proteins and displacement of BAX (as seen with BAD) or by direct activation of BAX and BAK (as observed with BID and BIM). BH3 mimetic peptides derived not only from BH3-only proteins, such as BAD
and BID but also from the multidomain BAX and BAK have been generated [210] . BH3 peptides longer than 14 amino acids can retain an ␣-helical structure and some biological activities [209] . For example, BH3 mimetic peptides induce oligomerization of BAX and BAK, permeabilization of MOM, and release of cytochrome c [211, 212] . [211, 212] . These different approaches enhanced the intracellular uptake of BH3 peptides. A chemical strategy, termed hydrocarbon stapling, was also explored, and resulted in maintenance of the ␣-helical conformation, increased stability, cell-permeability, increased affinity to multidomain BCL-2 member pockets and improved pharmacological properties [209] .
In principle, peptides containing BH3 domain sequences should be explored as pharmaceutical lead molecules. However, their use as therapeutic agents is limited by their unfavourable pharmacological properties, including poor cellular permeability, bioavailability, solubility and metabolic stability in vivo. Several methods have been tried to overcome these limitations. BH3 peptides have been tagged with peptide transduction domains from Drosophila antennapedia protein, human immunodeficiency virus-1 trans-activating (TAT) protein or an arginine homopolymer (R8) transduction domain
Natural and synthetic BH3 mimetic drugs
Natural compounds such as tetrocarcin A, a second metabolite derived from Actinomyces spp. [213] , chelerythrine [214, 215] and sanguinarine which are plant benzophenanthridine alkaloids, antimycin A, a Streptomyces-derived inhibitor of ubiquinone-cytochrome c oxidoreductase at the mitochondrial respiration chain [216] , gambogic acid derived from the gamboges resin of the tree Garcinia hanburyi [217] , and certain polyphenols such as gossypol, apogossypol (compounds from cotton seed extracts) [218] and purpurogallin (a natural compound extracted from Quercus sp. nutgall) [218] promote death by binding BCL-2 and BCL-xL and inhibiting their anti-apoptotic functions (Fig. 3) .
Computational molecular docking analysis predicted that antimycin A targets the BH3-binding pocket of the anti-apoptotic BCL-2 family molecules [216] . NMR binding studies with BCL-xL revealed that gossypol and purpurogallin also compete for the BH3-binding pocket [218] . [215] . [222] . Collectively these studies indicate that ABT-737 as a single agent shows strong potency against a variety of tumour types such as lymphoma, leukaemia, multiple myeloma and small-cell lung cancer and that when used in combination therapy it may help to overcome drug resistance phenotypes in additional tumour types [200, 220, 223] . The BH3 mimetic has also recently been shown to sensitise cancer cells to TRAIL [224] and to induce IMM permeabilization and mitochondrial swelling reminiscent of MTP in chronic leukaemia cells [225] . Even if the preclinical data strongly support a rationale for clinical trials with ABT-737, the compound has not yet entered clinical trials [226] .
Whereas some of these compounds act as 'true BH3 mimetics', others appear to inhibit anti-apoptotic BCL-2 family members without targeting the BH3-binding pocket per se. Indeed, chelerythrine and sanguinarine bind separately at the BH groove and BH1 region of BCL-xL respectively, as opposed to the BH3 binding cleft which is targeted by other known inhibitors of BCL-xL
At the moment, of all the above mentioned natural BH3 mimetic small molecules, only gossypol, in an oral form (AT-101) has advanced into clinical trials (phase I/II) for the treatment of patients with refractory metastatic breast cancer [219] and for the treatment of patients with Glioblastoma Multiforme in combination with the alkylating agent temozolomide with or without radiation therapy (www.clinicaltrial.gov). A recent highlight in the field is the development of ABT-737. ABT-737 is a cell permeating, synthetic BH3 mimetic that was designed by Oltersdorf et al. [220] using a NMR structure-based approach to target the BH3-binding groove on BCL-xL. It binds with high affinity in the subnanomolar range to BCL-2 and BCL-w. However, despite its high affinity for BCL-2, BCL-xL and BCL-w many cell types proved refractory to ABT-737. It appeared that the resistance reflects ABT-737's inability to target another pro-survival BCL-2 relative, MCL-1. Subsequently, down-regulation of Mcl-1 by several strategies was shown to confer sensitivity to ABT-737 [221]. Numerous studies have evaluated the merit of ABT-737 in triggering apoptosis via the mitochondrial pathways in cancer cell lines and mouse xenograft models
Targeting mitochondria directly: mitochondriotoxic compounds inducing mitochondrial membrane permeabilization
Shortly after the discovery that MOMP is a 'point of no return' [227] and that once it occurs cells die, mitochondria have become an attractive target to induce apoptosis (Fig. 3) [229] .
Peptide derivatives Peptides derived from viral proteins [228], from proteins of the PTP and natural as well as synthetic peptides have been shown to be able to kill mammalian cells by triggering MOMP. The human immunodeficiency virus, HIV-1 encoded apoptogenic protein Vpr induces MMP via interactions with VDAC and ANT [190]. The chimeric peptide TEAM-VP using the MMP-inducing sequence derived from Vpr and a tumour blood vessel RGD-like 'homing' motif has been engineered. This virus-derived mitochondriotoxic compound targets mitochondria of angiogenic endothelial cells to induce MOMP and the release of mitochondrial apoptogenic molecules resulting in apoptosis
Mastoparan, a peptide isolated from wasp venom (as well as its derivative mitoparan) has an ␣-helical structure and possesses positive charges clustered on one side of the helix. Mastoparan is the first peptide known to induce MOMP via interaction with VDAC in a CsA-regulated mechanism [230, 231] . A second amphipathic peptide, the signal sequence of cytochrome oxidase subunit IV from Neurospora crassa (pCoxIV, amino acids [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] , which targets subunit IV to its mitochondrial location has also been shown to increase the permeability of isolated mitochondria [232] .
A peptide structurally similar to Mastoparan, DKLAKLAKKLAK-LAK or (KLAKLAK)2 (K ϭ lysine, L ϭ alanine and A ϭ leucine) has recently been shown to disrupt mitochondrial membranes and directly permeabilize this organelle [233] . Moreover, when fused to targeting peptides that interact with surface receptors expressed on angiogenic endothelial cells in tumours (with the tumour blood vessel RGD-like 'homing' motif) [233] or on prostate vasculature (with the prostate-homing phage, SMSIARL) [234] , or even with a peptide that inhibits the ErbB-2 receptor kinase [235] [237] . [241] [242] [243] , and this finding may stimulate the development of a novel class of small anticancer compounds that inhibit the HK-VDAC interaction.
The jasmonates are a group of plant hormones which help regulate plant growth and development. Jasmonates include jasmonic acid and its esters, such as methyl jasmonate (MeJa). MeJa induces death in cancer cells, while being selectively inactive towards non-transformed cells [238]. MeJa acts directly on mitochondria derived from cancer cells in a PTPC-mediated manner [239]. MeJa binds to human HK isoforms I and disrupt its interaction with VDAC, causing the inhibition of glycolysis and the induction of MOMP [240]. MeJa has already been shown to have selective anticancer activity in preclinical studies
Small molecules
Conventional chemotherapeutic agents, such as 2-chloro-2Ј-deoxyadenosine (2CdA) [244] , topoisomerase II inhibitor etoposide (Vepeside, VP16) [245] which affects DNA replication, and paclitaxel (Taxol, TM) [246] [247] and erucylphosphohomocholine (ErPC3) [248] [249, 250] . Whether the apoptogenic or chemosensitizing effects of the above-mentioned agents are truly due to a direct effect on mitochondria, is at least in some cases, a matter of debate. For instance, the doses of PBR ligands required to obtain cytotoxic effects are several orders of magnitude higher than the Kd of the high-affinity PBR and in certain cases their cytotoxicity even appeared to be unrelated to PBR expression [251] .
which disrupts microtubule assembly can disrupt the integrity of mitochondria and induce cell death via the opening of the MTP pore. However, the high doses required to obtain this effect raise the question of whether these drugs in a clinical setup can induce cell death via MOMP. Synthetic ligands of the peripheral-type benzodiazepine receptor (PBR) such as the benzodiazepines (Ro5-4864), isoquinoline carboxamides (PK 11195), indoleacetamides (FGIN-1-27), phenoxyphenyl-acetamides (DAA1106), pyrazolopyrimidines (DPA-713)
A number of agents, for example lonidamine [252, 253] , alltrans-retinoic acid [254] , the synthetic retinoid RAR-␥ ligand 6-[3- (1-adamantyl)-4 -hydroxyphenyl]-2-naphtalene carboxylic acid (CD437) [252, 255] , arsenic trioxide (As2O3) [252] , 2CdA Cladribine and 2-choloro-2Ј-ara-fluorodeoxyadenosine (CaFdA) [244] , have been reported to induce a conformational change in the ANT leading to mitochondrial channel formation. Lonidamine enhances the apoptotic response to cisplatin, cyclophosphamide, doxorubicin, paclitaxel, melphalan and ␥-irradiation both in vivo and in vitro [253] . Lonidamine kills a wide range of tumour cells in vitro and in animal models. This drug in combination therapy is currently being tested in phase II/III trials for metastatic breast [256] , non-small cell lung cancer [257] , ovarian cancer [258] and glioblastoma [259] with encouraging results so far. Arsenite, the trivalent inorganic salt formed from arsenic trioxide, which is used to treat acute promyelocytic leukaemia [260] and has entered phase II clinical trials for multiple myeloma [261] [244, 262] .
, causes glutathione depletion, induces PTP opening and its effect is prevented by BCL-2. 2CdA and 2-choloro-2Ј-ara-fluorodeoxyadenosine (CaFdA) drugs are clinically used for the treatment of indolent lymphoproliferative diseases, they disrupt the integrity of mitochondria and induce the release of pro-apoptotic mitochondrial proteins from these organelles
A number of agents that act on mitochondria possess a steroid-like core structure. For instance, this applies to the above mentioned ANT ligands CD437 [252, 255] , all-trans-retinoic acid [254] as well avicins [263] , betulinic acid [264] and resveratrol [265] . [263] . The effect of Resveratrol (3, 5 ,4Ј-trihydroxy-trans-stilbene), a phytoalexin found in grapes and other plant food, is more complex as it has been shown to be able to both promote [266] and inhibit [267] the mitochondrial death pathways. Resveratrol treatment of isolated mitochondria also led to depolarization, suggesting that the drug may target mitochondria directly [265, 266] [268] , it has been shown promote an MPT-dependent release of cytochrome c and AIF from isolated mitochondria [269, 270] [269] and displays potent anticancer activities in vivo in a human colon tumour xenograft model [269] . (Fig. 3) . Because ⌬⌿m is often higher in malignant cells, lipophilic cations may selectively accumulate in their mitochondria, sparing the organelles of normal cells [271] . Several types of cancer cells have been described to accumulate such agents, e.g. rhodamine 123, to a higher level than normal cells [272] . Attempts have been made to use cationic lipophilic toxins as mitochondriotoxic agents. For instance, the pyridinium derivative F16 accumulates in the mitochondria and inhibits growth of human breast cancer cell lines [273] . MKT-077, a cationic rhodacyanine dye, is selectively toxic to cancer cells in vitro and in vivo [274] . MKT-077 activity has been associated with an effect on mitochondrial membranes and mitochondrial DNA [275] The antitumour effect of MKT-077 in xenografted mice models along with its selective accumulation in tumour mitochondria prompted its evaluation in the clinic. Renal toxicity encountered during the phase I trial, stopped further development of MKT-077 [276] [278] . The photoproduct of merocyanine 540 triggers cytochrome c release from isolated mitochondria and promotes apoptosis [279] .
Betulinic acid, a naturally occurring pentacyclic triterpenoid, induces apoptosis in tumour cells through the mitochondrial pathway. Combined treatment with betulinic acid and anticancer drugs acted in concert to induce loss of mitochondrial membrane potential and the release of cytochrome c and Smac from mitochondria. Isolated mitochondria from different cell types are permeabilized by betulinic acid, and this effect is prevented by CsA, the ANT ligand bongkrekate, as well as by BCL-2 overexpression [264]. It is unclear, however, through which receptor (if any) betulinic acid acts on mitochondria. Avicins, a novel plant-derived metabolite reduces energy metabolism in tumour cells by targeting the outer mitochondrial membrane and pushing cells towards the apoptotic pathway by permeabilization of the outer mitochondrial membrane
Cationic lipophilic agents The lipid composition of the IMM is very different from that of other intracellular membranes. Lipophilic cations can cross cellular membranes and accumulate in mitochondria driven by the mitochondrial membrane potential to induce MOMP
Photoactivation also enhances the mitochondrial toxicity of the cationic rhodacyanine MKT-077 [274] . Another cationic lipophilic dye, chloromethyl-X-rosamine (MitoTraker Red), a mitochondrion-selective fluorescent probe, has a strong photosensitising action. Photo-irradiation of intact cells loaded with MitoTraker Red induces depolarization of the IMM and swelling of mitochondria, subsequently resulting in apoptosis [280] . The photosensitizer hypericin detaches HKs from mitochondria [281] , whereas the phthalocyanine photosensitizer Pc4 causes the photochemical destruction of BCL-2 [282, 283] . [284, 285] .
Bypassing the mitochondria: mitochondrial pro-apoptotic factors as chemotherapeutic agents
MOMP results in the release of a plethora of cell death effectors from the intermembrane space. Such factors include Smac/ DIABLO, a protein that exerts much of its pro-apoptotic function by neutralizing IAPs that function as caspase inhibitors. Another pro-apoptotic factor released from permeabilized mitochondria is the AIF, a mitochondrial flavoprotein that translocates to the nucleus where it contributes to chromatin degradation
The binding of Smac/DIABLO to IAPs is mediated by a relatively short stretch of amino acids located in the N-terminus of the protein [286] . Several studies have shown that overexpression of Smac/DIABLO sensitizes neoplastic cells to apoptotic death [287] [288, 289] and glioblastoma cell lines [290, 291] . Similarly, a small Smac-mimic compound was able to increase the apoptotic effects of death stimuli [291] [295] . Likewise, the novel cationic amphiphilic compound atiprimod has been shown to exert antimyeloma effects in mouse experiments and its ability to kill mantle cell lymphoma cells has been attributed to the activation of the AIF-dependent pathway [296] . (Fig. 4) . [309] . NIM811 has been used with success to block PTP opening and prevent cell death in a number of experimental settings, including experimental liver transplantation [310] and spinal cord injury [311] . Another potent inhibitor of the pore is sanglifehrin A. This compound is a macrolide produced by actinomycetes that binds to CypD at a different site from CsA [312] and that has been shown to have cytoprotective effects in the reperfused heart [313] . [314] .
Therapeutic strategies that inhibit MOMP and cell death
Cyclosporin A and the inhibition of MPT
Another pharmacological inhibitor of PT with potential therapeutic applications is 5-(benzylsulfonyl)-4-bromo-2-methyl-3(2H)-pyridazinone
However, further work is required to ascertain its usefulness as a PT blocker.
Preconditioning of the heart protects by sparing mitochondria
Ischemic preconditioning (IPC) has long been known to provide substantial protection to the myocardium. By exposing the heart to one or more brief cycles of sub-lethal ischemia, this organ is protected from subsequent more prolonged and lethal ischemic insult as first reported by [315] . Mitochondria play a key role in IPC, and they have been shown to respond to IPC with diminished calcium sequestration [316] [317] [318] , improved respiration [319, 320] and desensitization to PT [313, 321] . Not surprisingly, considerable efforts have been devoted to the study of the role of PT in IPC. The sensitivity of cardiac mitochondria to undergo PT is consistently decreased after IPC [313, 321] 
Pharmacological IPC mimetics
A number of physiological ligands to plasma membrane receptors are released during ischemia and these are now known to play a key role in IPC (Fig. 4) [326, 327] . More recently, a similar mechanism of action on mitochondria through mitoKATP opening was reported with nicorandil [328] and bepridil [329] . [331] and to lead to mild uncoupling of the mitochondria [332] and the generation of ROS by complex III [333] . The opening of mitoKATP and mitoKCa 2ϩ by the anaesthetics appears to play an important role in the mechanism of protection and the observed prevention of PT during subsequent conditions of ischemia/reperfusion [334] . Isoflurane has also been shown in the heart to inhibit glycogen synthase kinase 3␤ [335] 
Minocycline
The semi-synthetic tetracycline antibiotic minocycline has been found in a large number of studies to provide protection from neurodegeneration and ischemic neuronal injury [338] , CD95-mediated hepatic injury [131] and hypoxic/ischemic renal and hepatic injury [310, 339] . Different mechanisms involving [340] , upregulation of anti-apoptotic BCL-2 [291] and inhibition of PT [310, 341] . The latter was attributed to minocycline decreasing mitochondrial Ca 2ϩ uptake [310, 341] 
